Health economy of the metabolic syndrome pandemic

Blood Pressure

Volumn 14, Issue 3, 2005, Pages 131-132

  Hedner, Thomas ^a   Kjeldsen, Sverre E ^a   Narkiewicz, Krzysztof ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; EDITORIAL; FINANCIAL MANAGEMENT; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFE EXPECTANCY; METABOLIC SYNDROME X; MORTALITY; PREVALENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK REDUCTION;

ADULT; ECONOMIC COMPETITION; HEALTH CARE COSTS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X;

EID: 22544467801     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037051510034310     Document Type: Editorial

References (23)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855-2864.
3. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: The role of risk factors. Prev Cardiol. 2002;5:188-199.
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-1276.
5. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordination Committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
7. World Health Organisation, International Society of Hypertension Writing Group. 2003 World Health Organisation (WHO)/Intemational Society of hypertension (ISH) statement on management of hypertension. J Hypertension. 2003;21:1983-1992.
8. O'Brien B. Patterns of European diagnosis and prescribing. London: Office of Health Economics, 1984.
9. OECD Health Data. Paris. Organization for Economic Cooperation and Development, 1997.
10. Ménard J, Corny PH, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens. 1992;6:447-458.
11. Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment. A review of methodological issues. Health Policy. 1991;19:55-78.
12. Moser M. The cost of treating hypertension. Can we keep it under control without compromising the level of care? Am J Hypertens. 1998;11:120S-127S.
13. Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden: An empirical investigation in primary health care. Scand J Prim Health Care. 1991;9:155-160.
14. Kawachi I, Malcom LA. The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal. J Hypertens. 1991;9:199-208.
15. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996;10:460-466.
16. Murray CJL, López AD, editors. The global burden of disease. Cambridge, MA: Harvard University Press, 1996.
17. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med. 1977;296:732-739.
18. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995;7:242-250.
19. Russell LB. Cost-effectiveness of antihypertensive treatment. General considerations. Hypertension. 1989;13(5 Suppl): 1141-1144.
20. Manica G, Grassi G. Considerations on current and future trials in hypertension. Blood Press. 1996;5:327-332.
21. Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens. 1996;14Suppl 2:S-47-S-54.
22. Zanchetti A. Cost-effectiveness of antihypertensive therapy: What message to patients and health sevices? J Hypertens. 1998;16Suppl 9:S21-S23.
23. Maynard A. The economics of hypertension control: Some basic issues. J Hum Hypertens. 1992;6:417-420.